Evogen
Evogen is a privately held neurology proteomics and genomics company that develops objective biomarker-based diagnostics (EvoScore), HD-PCR pathogen detection probes (HyBeacons), and bioaerosol air samplers (SpinCon) for healthcare providers, government biodefense, and food/agriculture customers.
- Company typePrivate
- Founded2001
- HeadquartersKansas City, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Evogen firmographics
Firmographics- Name
- Evogen
- Legal name
- Evogen, Inc
- Website
- https://evogen.com
- Company type
- Private
- Founded year
- 2001
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Evogen is a privately held neurology proteomics and genomics company that develops objective biomarker-based diagnostics (EvoScore), HD-PCR pathogen detection probes (HyBeacons), and bioaerosol air samplers (SpinCon) for healthcare providers, government biodefense, and food/agriculture customers.
- Ownership category
- akta.pro rank
Evogen industry classification
Industry- Product category
- Neurology Proteomics and Genomics Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Proteomics & Biomarker Analytical Testing (HLAGADAG)
- akta.pro secondary industries
- Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Prognostic & Risk Stratification Biomarkers (disease progression, recurrence risk) (HLAAAMAF)
Keywords
Where Evogen is headquartered
LocationHeadquarters
- HQ city
- Kansas City
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Evogen business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain
Revenue model
- Diagnostic Products and Reagent Technology: Evogen generates revenue through sale of diagnostic products including EvoScore for epilepsy diagnosis, HyBeacons PCR reagents, and SpinCon air sampling devices. These products target healthcare providers in precision medicine, infectious disease detection, and biothreat analysis.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Evogen product offering
Product offeringCore offering
Evogen develops and sells proprietary diagnostic products and reagent technologies focused on neurology proteomics and genomics. Its core offerings are EvoScore DX (proteomic biomarker-based epilepsy diagnostic), EvoScore GX (genomic testing for clinical practice), HyBeacons High Definition PCR probes for pathogen detection, and SpinCon portable air samplers for bioaerosol collection and biothreat detection.
Product overview
Evogen is a neurology proteomics and genomics company offering a unified portfolio of diagnostic products and technology platforms. The core offerings include EvoScore DX (proteomic biomarkers for epilepsy diagnosis), EvoScore GX (genomic testing for clinical practice), HyBeacons (High Definition PCR probes for pathogen detection), and SpinCon (bioaerosol collection air sampler). These products are organized across three service areas: Precision Medicine, Reagent Technology, and Threat Detection, serving healthcare providers, biodefense, infectious disease detection, food safety, animal health, and agriculture industries.
Differentiator
Problem solved
Functional benefit
Brands
- EvoScore: Objective measurement tool for rapid and accurate diagnosis of neurological diseases, particularly epilepsy.
- HyBeacons
- SpinCon
Products and services
- EvoScore DX Proteomic biomarker-based diagnostic solution for epilepsy diagnosis and seizure burden monitoring, providing objective measurements for rapid and accurate neurological disease diagnosis for healthcare providers.
- EvoScore GX Genomic testing solution advancing clinical practice through deep multiplexing capabilities for PCR-based diagnostics used for multiple targets.
- HyBeacons High Definition PCR (HD PCR) probes for rapid, highly accurate, and affordable pathogen detection. HyBeacons create robust fluorescent signals when probes bind to target DNA sequences and enable melt curve analysis post-amplification, supporting infectious disease, food safety, animal health, agriculture, and biodefense applications.
- SpinCon Portable, energy-efficient wet concentrator air sampler for collecting bioaerosols, particulate matter, and soluble vapors. The gold standard for collecting large quantities of airborne pathogens including anthrax, foot and mouth disease, citrus canker, avian influenza, and mold, for biodefense and threat detection applications.
Quantifiable outcome
- Proteomic biomarkers can distinguish between epileptic and psychogenic nonepileptic seizures
- +1 more outcomes
Companies that use Evogen
Customer profileSegments3 records
Ideal customer profiles3 records
Evogen technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature4 records
Evogen partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- UCBcoreEvogen and UCB announced a collaboration focused on diagnostics for epilepsy. UCB is a global pharmaceutical company focused on neurology and rare diseases, making this partnership strategically aligned with Evogen's precision medicine focus in epilepsy. The collaboration was announced in December 2016.
- LGC LimitedcoreEvogen is a licensee of HyBeacons and HyBeacons registered trademarks from LGC Limited. This licensing agreement provides Evogen access to High Definition PCR (HD PCR) probe technology for rapid and highly accurate pathogen detection in infectious diseases, food safety, animal health, agriculture, and biodefense applications.
Scale indicators1 record
Recent moves6 records
Expansion highlights5 records
Evogen competitors and assessment
Company assessmentDirect peers
- Exagen: Specialty diagnostics company developing biomarker-based tests for autoimmune and rheumatic diseases. Exagen's model of proprietary biomarker tests sold to specialty physicians parallels Evogen's EvoScore approach of neurology biomarker diagnostics for clinicians.
- Quanterix: Single-molecule biomarker detection platform with neurology applications including neurodegenerative disease diagnostics. Quanterix's Simoa technology competes in the same proteomic biomarker diagnostic space as Evogen's EvoScore platform for neurology indications.
- Bio-Rad Laboratories: Major manufacturer of PCR reagents and molecular diagnostics platforms. Bio-Rad offers Droplet Digital PCR and traditional PCR chemistries that overlap with Evogen's HyBeacons HD PCR reagent technology for pathogen detection applications.
- Bertin Technologies: Manufacturer of air sampling and biodefense instruments including bioaerosol collectors. Bertin competes directly with Evogen's SpinCon wet concentrator air sampler in the biothreat detection and bioaerosol collection market.
Others
- LGC Limited: UK-based life sciences measurement and testing company that owns the HyBeacons HD PCR technology licensed to Evogen. LGC is both a technology licensor and a peer in genomic/reagent products, making it strategically critical to Evogen's reagent business.
Broad incumbents
- BioFire Diagnostics (bioMérieux): PCR-based multiplex pathogen detection panels (FilmArray) used widely in clinical and biodefense settings. BioFire's syndromic panels overlap directly with Evogen's HyBeacons-based reagent technology targeting infectious disease detection.
- Natera: Molecular diagnostics company with proprietary PCR and NGS-based tests across multiple specialties. Natera's Signatera and other products parallel Evogen's EvoScore GX genomic testing approach to clinical diagnostics with deep multiplexing.
- Cepheid (Danaher): Market-leading GeneXpert PCR platform for infectious disease diagnostics. Cepheid is a broad incumbent in molecular diagnostics that overlaps with Evogen's PCR-based pathogen detection use cases across clinical and biodefense settings.
Emerging players
- NeuroPace: Medical device company focused on epilepsy with the RNS System for closed-loop neurostimulation. NeuroPace shares Evogen's neurology/epilepsy focus but addresses a different modality (devices vs. biomarker diagnostics), making it a relevant adjacent peer for understanding the epilepsy commercial landscape.
- InnovaPrep: Specialty manufacturer of air sampling and bioaerosol collection instruments including the Concentrating Pipette and related wet cyclone samplers. InnovaPrep is a direct peer in the bioaerosol/biodefense air sampling market where Evogen's SpinCon competes.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Evogen social profiles
Digital presenceEvogen financial estimates
Financial estimateRevenue estimate
Valuation estimate
Evogen leadership team
Management profileNumber of profiles
Profiles4 records
Evogen funding detail
Funding detailFunding overview
Funding rounds4 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Evogen M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Evogen
What does Evogen do?
Evogen develops and sells proprietary diagnostic products and reagent technologies focused on neurology proteomics and genomics. Its core offerings are EvoScore DX (proteomic biomarker-based epilepsy diagnostic), EvoScore GX (genomic testing for clinical practice), HyBeacons High Definition PCR probes for pathogen detection, and SpinCon portable air samplers for bioaerosol collection and biothreat detection.
Is Evogen a public or private company?
Evogen is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Evogen founded?
Evogen was founded in 2001. It employs 1 to 10 people.
Where is Evogen based?
Evogen is headquartered in Kansas City, United States, in the North America region.
How does Evogen make money?
One revenue line is on record: diagnostic Products and Reagent Technology.
Who are Evogen's main competitors?
Direct peers on record are Exagen, Quanterix, Bio-Rad Laboratories and Bertin Technologies. LGC Limited is listed as an others. Broad incumbents are BioFire Diagnostics (bioMérieux), Natera and Cepheid (Danaher). Emerging players are NeuroPace and InnovaPrep.
Does Evogen have an API?
No public API is recorded for Evogen.
What industry is Evogen in?
Evogen's product category is Neurology Proteomics and Genomics Diagnostics. Its primary akta.pro industry code is HLAGADAG, Proteomics & Biomarker Analytical Testing, with a secondary code of HLAAALAD, Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics). Its NAICS code is 325413 and its SIC code is 2835.